Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD/PD 2020
VIENNA, April 3, 2020 /PRNewswire/ — AXON Neuroscience SE (“Axon”) an industry leading, clinical stage biotech company at the forefront of treating and preventing Alzheimer’s Disease, presented the positive results of its Phase II trial for AADvac1, the first tau vaccine to treat and…
Comments Off on Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD/PD 2020